TY - JOUR T1 - The SumRank method efficiently detects valid pleiotropic variants using GWAS summary level data JF - medRxiv DO - 10.1101/2022.09.07.22279671 SP - 2022.09.07.22279671 AU - Sander Lamballais AU - Gennady V. Roshchupkin AU - Raymond A. Poot AU - Steven A. Kushner AU - M. Arfan Ikram AU - Hieab H. H. Adams AU - Henning Tiemeier Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/09/09/2022.09.07.22279671.abstract N2 - Genome-wide association studies (GWASs) have illustrated that pleiotropy is the norm rather than the exception in the genetic architecture of complex traits. Previous methods have been proposed to investigate cross-trait associations; however, these typically suffer from substantially inflated false positive rates, are limited to associations between only two traits, or examine only a subset of genome-wide variants. Here, we introduce SumRank, a novel method for discovering cross-trait associations based on p-values from GWAS summary statistics. Using numerical and genotype simulations, we demonstrated that SumRank had a near-zero false positive rate, in contrast to contemporary meta-analytical approaches that yielded severely inflated rates. We applied SumRank to GWAS summary data of eight psychiatric disorders and identified 515 independent pleiotropic variants across 175 loci, of which 92 were novel and 71 had previously been associated with only one disorder. Overall, SumRank provides a valid and efficient method for genome-wide discovery of pleiotropic variants that underlie a scalable number of traits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Netherlands Organization for Scientific Research (NWO/ZonMW grant 016.VICI.170.200 [SL, HT], NWO VENI 916.19.151 [SL, HA]).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used UK Biobank data, a public dataset which can be obtained through a data access application available at https://www.ukbiobank.ac.uk. We also used summary statistics from GWASs conducted by the PGC, which can be obtained from https://www.med.unc.edu/pgc/download-results/. This information has been included in the Data Availability section.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll summary statistics from the PGC can be obtained from https://www.med.unc.edu/pgc/download-results/. The raw UK Biobank data can be obtained through a data access application available at https://www.ukbiobank.ac.uk. ER -